MiNK Therapeutics Reports Second Quarter 2023 Results

-  Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center -  iNKT Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid...
-Today at 07:31 am- MarketScreener

Related Keywords

United States ,New York ,American ,Jennifer Buell ,Yelena Janjigian ,International Conference ,Nasdaq ,Mink Therapeutics Inc ,American Thoracic Society ,Company Updates ,American Association For Cancer Research ,American Society Of Gene ,Metastatic Gastric Cancer Planned ,Memorial Sloan Kettering Cancer ,Data Presented ,Solid Tumor Cancers ,Respiratory Distress ,Eliminated Tumors ,Chief Executive Officer ,Gastrointestinal Oncology ,American Association ,Cancer Research ,Annual Meeting ,American Society ,Cell Therapy ,Consolidated Statements ,Risk Factors ,Markets ,